Knockout validation coming for Bioss antibodies

As a dedicated researcher, you deserve extraordinary products in support of your studies. Bioss understands your concern and strives to meet your expectations every day, which is why we initiated knockout (KO) validation program on our selected products.

With the advance of biological discoveries, not only researchers demand more from their antibodies, but also the companies that produce them. Bioss seeks to improve the user experience by providing top quality product testing. In this pursuit, we recognize the need for more tailored validations of our antibodies against knockout, knock-in, and mutated targets. Knockout validated antibodies allow for increased experimental reliability and reproducibility. During the validation process, antibodies tested against wildtype cell lines are compared to those tested against knockout cell lines that don't express the target protein. A specific antibody should detect only the target from the wildtype and find nothing from the knockout. This process provides a reliable negative control for the antibody's target specificity.

Through a new partnership with EdiGene Inc. (http://www.edigene.com), a leader in genome-edited human cell lines, we have selected many most popular knockout lysates for our antibody validation program, with more expected in the future. Data gathered through such testing will afford a more robust understanding of each antibody's properties and allow researchers to make more informed purchases.

Our continued goal is to ensure our users the best quality products and information available. This effort lies at the heart of our company's mission — to develop and manufacture top quality antibodies that accelerate biological research and discovery. We are looking forward to the long-term collaboration with our most important partner: the worldwide community of scientists who trust our products in their labs each day and every day.